Labcorp to Introduce Combined Oncology Offering at 2021 ASCO® Annual Meeting

On June 2, 2021 Labcorp (NYSE: LH), a leading global life sciences company, reported the introduction of its combined Labcorp oncology platform at the virtual 2021 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting held June 4-8 (Press release, LabCorp, JUN 2, 2021, View Source [SID1234583420]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Labcorp’s oncology platform brings together the company’s leadership in diagnostic testing with its comprehensive drug development services, delivering targeted solutions for oncology by leveraging breakthrough science and insights from clinical and patient data to power better decisions and improved patient outcomes. Labcorp’s highly trained and specialized oncology team is led by Prasanth Reddy, M.D., MPH, a triple-board certified oncologist, and includes Robert Phillips, Ph.D., vice president and head of enterprise oncology.

"Advances in science have led to promising cancer-related discoveries, yet there is much more to do to in the field of oncology to find better treatments and improve lives," said Phillips. "Labcorp has a history of developing best-in-class diagnostics and drug development solutions that can help accelerate new therapy options for cancer patients. We are able to empower better decisions and make precision medicine available to more cancer patients by expanding access to diagnostic testing and clinical trial opportunities across communities."

Phillips will speak as part of the Industry Expert Theater1 on Monday, June 7, from 10-10:40 a.m. EDT. His presentation, Reimagining Precision Medicine Throughout a Patient’s Journey, will introduce the Labcorp oncology platform and highlight new, expanded testing and trial options. Immediately following the presentation, Phillips will be conducting a live audience Q&A session. Attendees will also have on-demand access to the presentation for the duration of the conference. Labcorp’s online exhibit for the ASCO (Free ASCO Whitepaper) Annual Meeting is available 24/7 between Friday, May 14, and Tuesday, July 6. The exhibit aims to educate attendees on testing options offered by Labcorp, as well as the wide-ranging support the company provides for oncology clinical trials. Attendees will be able to leave a virtual business card at the exhibit page to connect with Labcorp. To access the online exhibit and Dr. Phillips’ presentation, and to learn more about the conference, please visit View Source

Labcorp’s comprehensive oncology test menu to be discussed at the ASCO (Free ASCO Whitepaper) Annual Meeting includes the commercial introduction of OmniSeq INSIGHT—a pan-cancer, tissue-based sequencing test for patients with late-stage solid tumor cancers. The test helps physicians make decisions about therapeutic treatments and identify patients who may be eligible for any of several thousand ongoing clinical trials.

Labcorp also intends to highlight IntelliGEN Myeloid and liquid biopsy testing for lung cancer. IntelliGEN Myeloid is a next-generation sequencing (NGS) assay that evaluates 50 genes known to be useful in providing diagnostic, prognostic and predictive information for patients with myeloid malignancies. Liquid biopsy testing examines a blood sample for cancer cells, or pieces of DNA from a tumor circulating in the blood, in order to identify mutations and help select the most effective, targeted treatments. It is an increasingly viable, non-invasive testing option in cases where obtaining a tissue sample may be difficult or risky.

Labcorp Drug Development will contribute two online abstracts to the scientific program—e18608: "Mortality in adult patients with solid or hematological cancers and SARS-CoV-2 infection with a specific focus on lung and breast malignancies: A systematic review and meta-analysis," and e13584: "The role of digital clinical measures in improving cancer care and research."

Labcorp has also made a donation to Conquer Cancer, the ASCO (Free ASCO Whitepaper) foundation dedicated to conquering cancer throughout the world by funding breakthrough research and sharing cutting-edge knowledge.

ALUNBRIG® (brigatinib) Approved for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)-positive Metastatic Non-Small Cell Lung Cancer (NSCLC)

On June 2, 2021 Onco360, the nation’s largest independent Oncology Pharmacy, reported that it has been selected by Takeda to be a specialty pharmacy partner for ALUNBRIG (brigatinib), an oral therapy option for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) (Press release, Onco360, JUN 2, 2021, View Source;positive-Metastatic-Non-Small-Cell-Lung-Cancer-NSCLC [SID1234583419]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Onco360 is excited to become a specialty pharmacy provider for ALUNBRIG patients," said Benito Fernandez, Chief Commercial Officer, Onco360. "As a provider of this important treatment option for patients, Onco360 is committed to supporting the highly specialized needs of ALK-positive metastatic NSCLC patients and their physicians across the United States."

According to the National Cancer Institute’s (NCI) Surveillance, Epidemiology, and End Results (SEER) Program, approximately 235,760 patients will be diagnosed with lung cancer in 2021 with a corresponding 131,880 deaths. Approximately 85% of lung cancer cases are represented by NSCLC. When considering all subtypes of lung cancer as well as stages of the disease, lung cancer patients have a poor five-year overall survival (OS) of 21.7%. Unfortunately, 56% of lung cancer patients will have incurable, metastatic disease at the time of initial diagnosis.1 Approximately 4-to-5% of NSCLC patients have genetic mutations which can be classified as ALK-positive.2

ALUNBRIG is manufactured by Takeda, a commercial-stage biotechnology company. The FDA’s approval of ALUNBRIG is based upon the results of multiple clinical trials including the Phase III ALTA 1L (NCT02737501) clinical trial which demonstrated that ALUNBRIG administration resulted in a 51% improvement in progression-free survival (PFS) compared to XALKORI in treatment-naïve patients with ALK-positive metastatic NSCLC patients.3 For full prescribing information, visit ALUNBRIG.com.

Quanterix Chairman and CEO Kevin Hrusovsky to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference and Appear on the June 3 Episode of The Bio Report

On June 2, 2021 Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, reported that Chairman and Chief Executive Officer, Quanterix, Kevin Hrusovsky will be delivering a virtual presentation at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10th at 3:50pm ET (Press release, Quanterix, JUN 2, 2021, View Source [SID1234583418]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Attendees can access the public webcast at View Source or by visiting the News & Events page within the Investors section of the Quanterix website at View Source Replays of the webcast will be available on the Quanterix website for 90 days following the conference.

Additionally, Hrusovsky will appear on the June 3 episode of The Bio Report, a leading podcast that focuses on the intersection of biotechnology and business, science, and policy. The episode, which airs at 4:00 p.m., EDT, will be available to listen on demand at http://thebioreport.com/ or through the following podcast providers: Apple Podcasts, iHeart Radio, Google Podcasts, Soundcloud, and Stitcher.

Humanetics Corporation Receives Funding From Regenerative Medicine Minnesota to Study New Drug for Triple Negative Breast Cancer

On June 2, 2021 Humanetics Corporation (Humanetics) reported that it has received a business development grant from Regenerative Medicine Minnesota to conduct a series of nonclinical studies with its investigational drug, BIO 300 (Press release, Humanetics, JUN 2, 2021, View Source [SID1234583416]). The studies will evaluate the potential of BIO 300 to prevent metastasis of triple negative breast cancer to the lungs following radiotherapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Triple negative breast cancer is the deadliest and most clinically challenging subtype of breast cancer. Patients are commonly treated by surgery followed by radiotherapy. Unfortunately, one in three patients will experience metastasis, and one of the major metastatic sites is the lung. During breast cancer radiotherapy, the lungs may be incidentally exposed to radiation, and the ensuing damage primes the lungs for tumor cell metastasis. The five-year survival rate of metastatic triple negative breast cancer is 11%. The regenerative properties of BIO 300 allow it to protect normal tissues, including the lungs, from harmful radiation exposure. These studies will assess the potential of BIO 300 to mitigate lung damage following radiation exposure to prevent metastasis of triple negative breast cancer.

The studies will be conducted by Dr. Cheuk Leung and his team at the University of Minnesota. Research in the Leung Lab focuses on understanding the cellular mechanisms of breast cancer to better treat disease and reduce cancer relapse. Dr. Leung is one of the leading experts in 3D organotypic cell models, which recapitulate the tumor microenvironment. The Leung Lab will utilize these model systems to study the effect of radiation and subsequent BIO 300 intervention on tumor metastasis.

BIO 300 is under advanced development by Humanetics as a medical countermeasure to protect the body from harm caused by ionizing radiation. It was initially discovered by researchers at the U.S. Department of Defense through their efforts to create radioprotective drugs for the military. BIO 300 has been shown to mitigate inflammation of the lungs (pneumonitis) and pulmonary fibrosis caused by radiation. Radiation-induced injury to normal lung tissue is similar to the toxicities associated with lung cancer radiotherapy, and to lung injury caused by COVID-19. Humanetics has therefore further expanded applications for the drug into cancer radiation therapy and COVID-19. Humanetics recently completed a clinical trial in lung cancer patients who developed pulmonary injury related to their radiation treatments (NCT02567799) and is currently enrolling a clinical trial in COVID-19 patients recently discharged from the hospital who are at risk of developing long-term pulmonary complications (NCT04482595).

Lucence Presents Real-World Evidence on Applications of Liquid Biopsy at 2021 ASCO, Announces Formation of Medical Advisory Board

On June 2, 2021 As part of the 2021 ASCO (Free ASCO Whitepaper) Annual Meeting, precision oncology company Lucence reported that it is sharing real-world data supporting clinical applications of its amplicon-based liquid biopsy assay (Press release, Lucence, JUN 2, 2021, View Source [SID1234583415]). The data will be presented in on-demand virtual poster sessions, available beginning June 4 at 9 AM EDT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Lucence is also announcing the formation of a medical advisory board in the United States. Lucence’s Medical Advisory Board will be tasked with providing strategic, patient-centered guidance on research, development, and clinical applications of amplicon-based liquid biopsy tests. Dr. Gilberto Lopes of the University of Miami will join as an advisor.

Gilberto de Lima Lopes Jr., MD, MBA, FAMS is Interim Chief for the Division of Medical Oncology, Medical Director for International Programs and Associate Director for Global Oncology at the Sylvester Comprehensive Cancer Center, and Professor of Clinical Medicine at the Miller School of Medicine at University of Miami. Dr. Lopes’ career spans North America, Latin America, and Asia, and he has dedicated much of his time to the issues of cancer control and access to medications in low- and middle-income countries. Dr. Lopes is the Editor-in-Chief of ASCO (Free ASCO Whitepaper)’s Journal of Global Oncology.

"Dr. Lopes is a world-leading oncologist and is committed to the shared vision of accurate, accessible, and affordable precision cancer care for patients everywhere. We are honored to have him join Lucence’s Medical Advisory Board in the United States and know his insights will help inform our clinical approach in the months and years to come," said Min-Han Tan, Founding CEO and Medical Director of Lucence.

Lucence will be sharing two abstracts as part of Virtual 2021 ASCO (Free ASCO Whitepaper) highlighting the use of its ultrasensitive amplicon-based next-generation sequencing (NGS) assay, LiquidHALLMARK, for advanced cancers in real-world settings. Findings of both abstracts support the clinical utility of circulating tumor DNA (ctDNA) detection for non-small cell lung cancer (NSCLC) diagnosis and treatment selection.

The first abstract (#3062), authored by Jonathan Poh and contributors, Comprehensive molecular profiling of advanced cancers in a real-world setting using an ultrasensitive amplicon-based next-generation sequencing (NGS) liquid biopsy assay, detected ctDNA in 70% of cancer samples. In ctDNA-positive lung cancer (n=484), 75% of samples harbored one or more actionable targets for an FDA-approved therapy. Of the 392 patients being treated with EGFR tyrosine kinase inhibitors (TKIs), 29% harbored a mutation associated with EGFR TKI resistance. The data show how liquid biopsy can detect emerging resistance to therapy and suggest that LiquidHALLMARK can be a useful clinical tool in monitoring response to treatment.

The second abstract to be presented (#3042), in collaboration with the Bivona Lab at UCSF, is authored by Wei Wu and contributors. Targeted ctDNA sequencing analysis reveals concurrent genomic alterations and its impact on TKI and immune checkpoint inhibitor therapy in advanced NSCLC from an Asian population characterizes the ctDNA-derived genetic landscape of advanced NSCLC from a real-world population. Using Lucence’s LiquidHALLMARK assay, 76% of lung cancer patients were found to have at least 1 actionable mutation relevant to targeted therapy. Investigators also reported the finding of a novel PD-L1 structural rearrangement potentially associated with immune evasion.

As a follow up to Lucence’s programming for 2021 ASCO (Free ASCO Whitepaper), on June 29, 2021 at 8:30 PM EDT, Lucence will host New Frontiers in Liquid Biopsy for Lung Cancer, a webinar covering current and cutting-edge applications of liquid biopsy in thoracic oncology. Panelists will include Narjust Duma, MD, Assistant Professor of Medicine and Thoracic Oncology at the University of Wisconsin Carbone Cancer Center, Professor Tony Mok, MD, FRCPC, FASCO, Chairman of the Department of Clinical Oncology at the Chinese University of Hong Kong, and Christine M. Lovly, MD, PhD, Co-Leader of the Translational Research and Interventional Oncology Research Program and Associate Professor of Medicine at Vanderbilt University. Gilberto Lopes, MD, MBA, Interim Chief of Medical Oncology and Professor at the Miller School of Medicine of the University of Miami will moderate. For more information and to register for the webinar, please visit the Zoom registration page or email [email protected].